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M edications, especially proton pump inhibitors (PPIs), have a prominent role in the treatment of patients with laryngeal/voice disorders. Half of all patients presenting to general medical providers (GMPs) and otolaryngologists for voice-related complaints undergo medication trials, of which PPIs are common. 1, 2 Furthermore, the frequent use of PPIs is associated with significant health care costs, accounting for 10% of the direct costs in the evaluation and treatment of patients with laryngeal/voice disorders. 3 Yet, for patients with laryngeal/voice disorders, the practice patterns of GMPs and otolaryngologists suggest uncertainty surrounding the indications for PPI use, with the subsequent potential for inappropriate use. [4] [5] [6] [7] [8] Thus, the frequent use of PPIs in the treatment of voice disorders has important public health implications for patients and society.
Beyond cost concerns, there is growing interest in and awareness of the potential adverse effects of PPIs. In a systematic review of systematic reviews, community-acquired pneumonia (CAP) was 1 of the 3 most commonly reported adverse events, with bone fractures and enteric infections. 9 Alterations in the bacterial microbiome from acid suppression was proposed as a possible mechanism of increased CAP risk with PPI use. [10] [11] [12] In particular, CAP may have a substantial impact at the population level; it also brings additional morbidity, mortality, and associated health care costs. 9, 13 Despite the frequency of PPI use, there are no data concerning the relationship between PPIs and CAP at the population level for a cohort of patients with laryngeal/voice disorders. Understanding this association in this patient population is an important consideration for patients and providers when deciding about PPI treatment. The MarketScan database-a large national administrative US claims database-has been a useful means for exploring adverse events in diverse patient populations during real-world care.
14, 15 The purpose of this study is to assess the association between PPI treatment and CAP within a cohort of patients with laryngeal/voice disorders.
Methods
This study was approved by the Duke University Medical Center Institutional Review Board. The data set of the MarketScan Commercial Claims and Encounters Database and the MarketScan Medicare Supplemental and Coordination of Benefits Database was retrospectively analyzed for January 1, 2010, to December 31, 2014. Health care claims are representative of typical clinical care. 16 The MarketScan databases (Truven Health Analytics and IBM Watson Health, Ann Arbor, Michigan) encompass the average annual health care claims, including pharmacy, of roughly 59 million individual employees \65 years of age, Medicare beneficiaries 65 years of age, and their dependents, integrated from all care providers and linked to health care utilization at the patient level.
Patients were included for analysis if (1) they had a diagnosis of at least 1 ICD-9-CM code (International Classification of Diseases, Ninth Revision, Clinical Modification) for a laryngeal/voice disorder ( Table 1) per outpatient encounter regardless of provider type; (2) they had 12 months of continuous enrollment prior to the index date, defined as the first laryngeal/voice disorder diagnosis; (3) they were 18 years of age at the index date; (4) they had no diagnosis of CAP in the 12-month pre-index date period; and (5) they had prescription claims completely captured by the MarketScan databases from 1 year preindex to end of follow-up. Patients were followed for the occurrence of CAP until the end of continuous enrollment or the end of 3-year follow-up. Because patients with a brainstem stroke may have a disordered voice from nucleus ambiguus involvement, codes 438.10 and 438.19 were included (late effects of cerebrovascular disease, speech and language deficit unspecified).
Data were collected for age, sex, index date laryngeal diagnosis, geographic region (divided into 4 census regions: northeast, north central, south, and west), urban versus rural status (based on residence in a metropolitan statistical area), and employment status (retired, employed, dependent, disabled). Comorbid disease was determined during the 12-month pre-index date period across outpatient and inpatient settings by creating a set of binary indicator variables with the categories and enhanced ICD-9-CM coding from the Elixhauser index. 17 Number of visits was determined by counting the unique outpatient and inpatient encounters during the 12-month preindex period, which can serve as a proxy for general health. 18 The presence of CAP was occurrence of ICD-9-CM codes for CAP (Table 1 ) during the 3-year post-index date period. The primary outcome is the time from index date to CAP, and patients were censored at disenrollment or the end of 3-year follow-up. The primary exposure of this study is the prescription of a PPI. The generic identification numbers according to the MarketScan database dictionary were used to identify PPIs. The number of PPI prescriptions and the timing of PPI prescriptions relative to the index date were determined. Prescription of a PPI after the index date was included in the analysis as a time-varying covariate, and the time of the first prescription after the index date was used. We made the assumption that once a PPI was initiated, exposure was not discontinued until the end of 3-year follow-up or censoring. Separate analyses were conducted for patients with and without PPI prescriptions within the 1-year pre-index date period.
Summary statistics were calculated. To examine the relationship between PPI and the risk of CAP, a time-dependent Cox regression model was performed with PPI treatment as a time-varying covariate. This model adjusted for age, sex, region, metropolitan statistical area, employment status, index laryngeal/voice diagnoses, gastroesophageal reflux, number of preindex encounters, and 29 comorbid conditions (see Supplemental Table S1 in the online version of the article). In addition, to evaluate the effect of PPI treatment on CAP and account for treatment selection bias for timedependent treatments, a propensity score-based approach with a marginal structural model (MSM) was applied. An MSM uses the inverse probability of treatment weighting (IPTW) and the inverse probability of censoring weighting (IPCW) to create a synthesis sample in which treatment selection is independent of patients' baseline characteristics and no censoring occurs. For each 60-day interval, we modeled the probability of receiving a PPI given the patients' covariates per logistic regression, and only patients not previously taking a PPI were included in the model. The predicted probability of receiving a PPI at each time point was then used to construct the IPTW. Similarly, we modeled the probability of not censoring based on patients' covariates at each time interval using patients who were still in the study (uncensored), and we used the predicted probability to construct IPCW. Additional models were fit to estimate the probability of PPI or not censoring without any covariates for each time point, and the predicted probabilities were used to stabilize the IPTW and IPCW. The final weights were then computed by cumulatively multiplying the stabilized IPTW and IPCW at each time interval. The hazard ratios for PPI use and covariates were estimated by fitting a weighted pooled logistic regression model that included baseline covariates, time-dependent PPI use, and a smooth function of time (restricted cubic splines with 5 knots placed at Harrell's locations). To examine the robustness of correct CAP diagnosis, sensitivity analyses were conducted by treating patients with only 1 CAP diagnosis as not experiencing CAP. MarketScan database management and statistical analysis were performed with SAS 9.4 (SAS Institute Inc, Cary, North Carolina). A 2-sided significance level of 0.05 was used for all statistical tests.
Results
A yearly mean of 59,400,337 unique patients was enrolled in the MarketScan databases from January 1, 2010, to December 31, 2014, with 745,955 (1.3%) unique patients having an initial laryngeal/voice disorder. The cohort selection process is shown in Figure 1 , resulting in 392,355 unique cases of laryngeal/voice disorders.
Patient demographics are displayed in Table 2 . A total of 188,128 (47.9%) patients with laryngeal/voice disorders had a PPI prescription. Of these patients, 55% had a PPI prior to the index date, with a median 3 prescriptions (interquartile range [IQR], 1-5); 40.8% had a PPI on the index date or within 2 weeks after; and 77.8% had a PPI from 2 weeks after the index date to the end of follow-up, with a median 4 prescriptions (IQR, 2-7). A PPI was usually prescribed for 30 days (median day supply, 30 days; IQR, 30-90 days). Patients with laryngeal/voice disorders who had a PPI prior to the index date were older (median age, 57 vs 51 years); they had a lower proportion of acute laryngitis on the index date (6.4% vs 10.4%); more of them were retired (25.6% vs 18%); a higher proportion had benign laryngeal/ vocal fold pathology (23.2% vs 20.0%) and chronic laryngitis (15.2% vs 13.3%) on the index date; and a higher proportion had gastroesophageal reflux (58.6% vs 21.2%) and more visits before the index date (median, 19 vs 11) . Patients with pre-index date PPI use were sicker than patients without, demonstrating a higher proportion of congestive heart failure (4.5% vs 2.7%), cardiac arrhythmia (12.7% vs 8.2%), valvular disease (7.6% vs 4.8%), for those without preindex PPI use. Given the differences in patient characteristics and comorbidities, our models examining the relationship between PPI use and CAP were performed on each group separately. Table 3 displays the association between PPI use on CAP, based on at least 1 CAP diagnosis, and a time-dependent Cox model and an MSM adjusting for confounders. At any given time, the likelihood of CAP for a person who had already received a PPI is 30% to 50% higher than for a person who has not yet had a PPI but may receive one later, among patients without and with pre-index date PPI use, respectively. The hazard ratios from the MSM were slightly different than those of the time-dependent adjusted Cox model; however, both showed a higher likelihood of CAP with PPI use, and this observation persisted when 2 separate CAP diagnoses were required to denote a CAP event.
Discussion
PPIs have a prominent place in the treatment of patients with laryngeal/voice disorders. This is concordant with our finding that approximately half of our patient cohort had a PPI prescription as part of its treatment. This high rate of PPI use is consistent with prior survey studies and realworld evaluations of practice patterns among GMPs and otolaryngologists. 2, 4, 6, 19, 20 The pervasiveness of PPI treatment, however, may expose patients with laryngeal/voice disorders to adverse effects. In a recent survey of internist members of the American College of Physicians, 98% reported having some concern about the adverse effects of PPIs, with 63% altering the dose, 52% switching to H2 blockers, and 44% discontinuing the PPI. 21 Moreover, patients are becoming more knowledgeable about their health care and may also have concerns about PPI treatment. 22 An association between PPI use and an increased risk for CAP was observed in our cohort with laryngeal/voice disorders. Because we could not precisely determine the reason for PPI prescription, given the limitations of the database, we examined the association between CAP and PPI use in 2 subgroups based on the relationship between PPI claims and the index date. As mentioned, differing demographic and comorbidity characteristics between patients with and without pre-index date PPI claims necessitated examining the relationship between PPIs and CAP per subgroup. From these analyses, we found an absolute risk of CAP, based on at least 1 CAP diagnosis, of 5.3% and 4.0% between patients with and without preindex PPI use, respectively. We observed a similar association between CAP diagnosis and PPI use in the subgroup with and without PPI use prior to the index laryngeal/voice diagnosis ( Table 3) . Furthermore, 2 analytic approaches identified a similar increased association between CAP diagnosis and PPI use.
Various reasons may explain the association between CAP and PPI use. A pooled odds ratio of 1.04 to 1.92 for CAP with PPI use was found in a systematic review of systematic reviews. 9 However, PPI claims are a proxy measure for actually taking the PPI. Thus, PPI use was treated as a binary time-varying variable with its value changed at the time of first postindex PPI prescription. Medication adherence, including if and when patients discontinued PPIs, could not be known, which prevented precise estimates of PPI exposure. Our assumption of continuous PPI exposure until follow-up or censoring could have overstated the PPI exposure. Furthermore, observational population-based studies found higher rates of CAP with PPI use among patients with recent use versus longterm current PPI use, which calls into question a true causal association. 10, 11, 23 We could not examine issues such as a doseresponse relationship between the length of PPI use and higher dosing regimens on CAP occurrence. It also is possible that the association between CAP and a PPI is correlative, as patients may have been started on PPIs for symptoms such as cough and dysphonia, which were misattributed to reflux but were actually early signs of CAP. 24 Although this potential scenario cannot be evaluated in the current data source, it could indicate possible inappropriate PPI use instead of a causal association between PPI use and CAP occurrence. Although we attempted to control for comorbid disease and care-seeking behavior, PPIs may be a marker for sicker individuals, who may be at increased risk for CAP irrespective of PPI use. In addition, randomized studies examining pneumonia rates among patients receiving PPIs versus placebo for stress ulcer prophylaxis did not find increased pneumonia rates in PPI use. 25, 26 Further investigation is needed to evaluate the nature of the association between PPI use and CAP among patients with laryngeal/voice disorders.
The association between CAP diagnosis and PPI use in laryngeal/voice disorders may be useful in guiding treatment decisions. For instance, the potential for misdiagnosis and inappropriate PPI treatment exists among GMPs who do not routinely visualize the larynx. 4, 6 For patients with laryngeal/ voice disorders who saw GMPs, received associated PPI treatment, and subsequently had otolaryngology evaluation, otolaryngologists more frequently diagnosed laryngeal structural abnormalities, neuromuscular impairment, and multiple laryngeal diagnoses. 7 Likewise, prior investigations focused on otolaryngology care found a high rate of diagnosis change among patients with laryngeal/voice disorders initially treated with PPIs, suggesting that such treatment may not have been needed. [27] [28] [29] The association between PPI use and CAP occurrence, combined with the possible misuse of PPIs, should caution GMPs and otolaryngology providers when considering PPI treatment. Although beyond the scope of this study, a careful assessment of the possible role of reflux in a patient's presentation through objective testing may be necessary to determine the need for PPI.
Given that our study cannot prove causation between PPI use and CAP risk and with acknowledgment that the benefits of PPIs may outweigh their risk for patients with strong indications for PPI treatment, the following recommendations may reduce potential CAP among patients with laryngeal/voice disorders. (1) Patients already taking PPIs or who have PPIs initiated should be followed and doses reduced to the minimum effective dose based on symptom improvement. 25, 30 If patients cannot reduce their PPI doses, objective reflux testing can examine the correlation between reflux events and patient symptoms and may lead to consideration of alternative diagnoses and treatments. 24 (2) Providers should have discussions with patients about specific PPIweaning protocols to help reduce rebound reflux symptoms when the dose is tapered and thus the resulting persistent dependence on PPIs. 31 Having shared decisions between patients and providers can lead to more informed decisions regarding PPI treatment.
Certain methodologic issues must be acknowledged. As mortality could be tracked in only the inpatient setting in this database, death was not incorporated as a competing risk. However, those who died were censored when continuous enrollment ended. While we captured comorbidity data during the 1-year pre-index date period, potential comorbid diseases may not have been counted if comorbidity-related patient encounters did not occur during this time. Although laryngeal/ voice diagnoses and other confounders may change over time, we considered PPI use as the only time-dependent event; specifically, we assumed that after the first time that a PPI was prescribed, the exposure and at-risk period for CAP continued until the end of follow-up. We were not able to determine how the diagnosis of CAP was made; thus, we present results where CAP diagnosis was based on at least 1 CAP ICD-9-CM code and at least 2 CAP ICD-9-CM codes. Although over-thecounter PPI use could not be assessed, over-the-counter PPI dosing is often lower and of shorter duration than PPI prescriptions and unlikely to be associated with CAP. 32, 33 As patients had commercial health insurance or supplemental Medicare, results may not be generalizable to patients without health insurance, the broader Medicare population, or patients with Medicaid. While there could still be unmeasured confounders that influenced our results, 2 analytic techniques were employed, and similar results were noted. These limitations notwithstanding, our study provides new insights regarding the potential association of CAP associated with PPI use in a broad cohort of patients with laryngeal/voice disorders during real-world care.
Conclusions
PPI use was pervasive in the real-world treatment of a cohort of patients with laryngeal/voice disorders, with half having PPI treatment. Both the patients who had a PPI initiated before the index laryngeal/voice diagnosis and those who had PPI treatment on or after the index date experienced a roughly 3% to 5% 3-year absolute risk for CAP and a 30% to 50% increased likelihood of CAP when compared with patients who had not had PPI prescriptions, with analyses adjusted for important sociodemographic and clinical characteristics. Furthermore, the association between CAP diagnosis and PPI use was consistent across the time-dependent Cox and MSM analyses. Further investigation is needed to explore the impact of dosing regimen, rates of other reported adverse events potentially related to PPIs, and which patients with laryngeal/voice disorders may be most susceptible for PPI-related adverse events.
Author Contributions
Seth M. Cohen, conception, design, analysis, interpretation, drafting, final approval; Hui-Jie Lee, conception, design, analysis, interpretation, revising, final approval; David A. Leiman, conception, design, analysis, interpretation, revising, final approval; Nelson Roy, conception, design, analysis, interpretation, revising, final approval; Stephanie Misono, conception, design, analysis, interpretation, revising, final approval.
Disclosures
Competing interests: Stephanie Misono, National Institutes of Health (NIH) research grant K23DC016335.
Sponsorships: None.
Funding source: This study was funded by the American Academy of Otolaryngology-Head and Neck Surgery. This study was made possible by grant UL1TR001117 from the National Center for Advancing Translational Sciences, a component of the NIH and the NIH Roadmap for Medical Research, as well as NIH grants ULI RR033183 and KL2 RR0333182. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Center for Advancing Translational Sciences or the NIH.
Supplemental Material
Additional supporting information is available in the online version of the article.
